Cargando…

Cytotoxic and targeted therapy for BRCA1/2-driven cancers

Tumors arising in BRCA1/2 germline mutation carriers usually demonstrate somatic loss of the remaining BRCA1/2 allele and increased sensitivity to platinum compounds, anthracyclines, mitomycin C and poly (ADP-ribose) polymerase inhibitors (PARPi). Exposure to conventional platinum-based therapy or P...

Descripción completa

Detalles Bibliográficos
Autor principal:	Imyanitov, Evgeny N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8399736/ https://www.ncbi.nlm.nih.gov/pubmed/34454564 http://dx.doi.org/10.1186/s13053-021-00193-y

Ejemplares similares

Cytotoxic and targeted therapy for hereditary cancers
por: Iyevleva, Aglaya G., et al.
Publicado: (2016)

Breast cancer therapy for BRCA1 carriers: moving towards platinum standard?
por: Imyanitov, Evgeny N
Publicado: (2009)

Mechanisms of acquired resistance of BRCA1/2-driven tumors to platinum compounds and PARP inhibitors
por: Imyanitov, Evgeny, et al.
Publicado: (2021)

Neoadjuvant therapy of BRCA1-driven ovarian cancer by combination of cisplatin, mitomycin C and doxorubicin
por: Gorodnova, Tatiana V., et al.
Publicado: (2021)

Drug therapy for hereditary cancers
por: Imyanitov, Evgeny N, et al.
Publicado: (2011)

Cancer Therapy Guided by Mutation Tests: Current Status and Perspectives
por: Aleksakhina, Svetlana N., et al.
Publicado: (2021)

Systemic therapy for hereditary cancer
por: Imyanitov, Evgeny N
Publicado: (2012)

Pancreatic Cancer: BRCA Targeted Therapy and Beyond
por: Keane, Fergus, et al.
Publicado: (2023)

Systemic treatment for hereditary cancers: a 2012 update
por: Imyanitov, Evgeny N, et al.
Publicado: (2013)

Gastric Cancer Risk and Pathogenesis in BRCA1 and BRCA2 Carriers
por: Buckley, Kole H., et al.
Publicado: (2022)

BRCA1-deficient breast cancer cell lines are resistant to MEK inhibitors and show distinct sensitivities to 6-thioguanine
por: Gu, Yuexi, et al.
Publicado: (2016)

Molecular testing for colorectal cancer: Clinical applications
por: Imyanitov, Evgeny, et al.
Publicado: (2021)

The Landscape and Therapeutic Targeting of BRCA1, BRCA2 and Other DNA Damage Response Genes in Pancreatic Cancer
por: Voutsadakis, Ioannis A., et al.
Publicado: (2023)

High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients
por: Suspitsin, Evgeny N, et al.
Publicado: (2009)

“Lazarus Response” to Olaparib in a Virtually Chemonaive Breast Cancer Patient Carrying Gross BRCA2 Gene Deletion
por: Moiseyenko, Vladimir M, et al.
Publicado: (2018)

Screening BRCA1 and BRCA2 Mutation Carriers for Breast Cancer
por: Warner, Ellen
Publicado: (2018)

A DNA Repair BRCA1 Estrogen Receptor and Targeted Therapy in Breast Cancer
por: Ratanaphan, Adisorn
Publicado: (2012)

Discrimination between Complete versus Non-Complete Pathologic Response to Neoadjuvant Therapy Using Ultrasensitive Mutation Analysis: A Proof-of-Concept Study in BRCA1-Driven Breast Cancer Patients
por: Sokolenko, Anna P., et al.
Publicado: (2023)

BRCA1 4153delA founder mutation in Russian ovarian cancer patients
por: Krylova, Nadezhda Yu, et al.
Publicado: (2006)

The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers
por: Cavanagh, Helen, et al.
Publicado: (2015)

Hereditary Ovarian Carcinoma: Cancer Pathogenesis Looking beyond BRCA1 and BRCA2
por: Samuel, David, et al.
Publicado: (2022)

Distribution of BRCA1 and BRCA2 Mutations in Asian Patients with Breast Cancer
por: Kim, Haeyoung, et al.
Publicado: (2013)

The importance of BRCA1 and BRCA2 genes mutations in breast cancer development
por: Mehrgou, Amir, et al.
Publicado: (2016)

Mutations of BRCA2 in canine mammary tumors and their targeting potential in clinical therapy
por: Thumser-Henner, Pauline, et al.
Publicado: (2020)

Exploiting DNA Damage Repair in Precision Cancer Therapy: BRCA1 as a Prime Therapeutic Target
por: Raimundo, Liliana, et al.
Publicado: (2021)

Experimentally-driven mathematical modeling to improve combination targeted and cytotoxic therapy for HER2+ breast cancer
por: Jarrett, Angela M., et al.
Publicado: (2019)

Integrative Genomic Tests in Clinical Oncology
por: Imyanitov, Evgeny, et al.
Publicado: (2022)

The pathology of familial breast cancer: The pre-BRCA1/BRCA2 era - historical perspectives
por: van de Vijver, Marc J
Publicado: (1999)

Management Strategies of Breast Cancer Patients with BRCA1 and BRCA2 Pathogenic Germline Variants
por: Edaily, Sarah, et al.
Publicado: (2022)

A porcine model system of BRCA1 driven breast cancer
por: Donninger, Howard, et al.
Publicado: (2015)

BRCA1/BRCA2 Pathogenic Variant Breast Cancer: Treatment and Prevention Strategies
por: Lee, Anbok, et al.
Publicado: (2020)

Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2
por: O’Mahony, Denise G., et al.
Publicado: (2023)

BRCA1, BRCA2 and their possible function in DNA damage response
por: Kote-Jarai, Z, et al.
Publicado: (1999)

The Breast Cancer Protooncogenes HER2, BRCA1 and BRCA2 and Their Regulation by the iNOS/NOS2 Axis
por: Lin, Katie, et al.
Publicado: (2022)

PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting
por: Dziadkowiec, Karolina N., et al.
Publicado: (2017)

Future possibilities in the prevention of breast cancer: Intervention strategies in BRCA1 and BRCA2 mutation carriers
por: Eeles, Rosalind A
Publicado: (2000)

Targeting BRCA1 and BRCA2 Deficiencies with G-Quadruplex-Interacting Compounds
por: Zimmer, Jutta, et al.
Publicado: (2016)

PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer
por: Annunziata, Christina M, et al.
Publicado: (2010)

BRCA1 and BRCA2 mutations in Iranian breast cancer patients: A systematic review
por: Neamatzadeh, Hossein, et al.
Publicado: (2015)

A Comprehensive Focus on Global Spectrum of BRCA1 and BRCA2 Mutations in Breast Cancer
por: Karami, Fatemeh, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_t2i5mqr31cl0u4vcdd562jbf4i